Irreversible EGFR inhibitors in the treatment of advanced NSCLC.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Current pharmaceutical design

• Publication date

  2014-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/13816128113196660764PMID 24138713
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

  2012cited by this paper
• Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

  2012cited by this paper
• Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)

  2012cited by this paper
• Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

  2012cited by this paper
• The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer.

  2011cited by this paper
• Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.

  2011cited by this paper
• The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.

  2010cited by this paper
• Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

  2010cited by this paper
• Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.

  2010cited by this paper
• A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer.

  2010cited by this paper
• Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

  2010cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

  2009cited by this paper
• A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

  2009cited by this paper
• Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

  2008cited by this paper
• EGFR antagonists in cancer treatment.

  2008cited by this paper
• BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

  2008cited by this paper
• Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.

  2007cited by this paper
• PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

  2007cited by this paper
• Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors

  2007cited by this paper
• Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

  2007cited by this paper
• The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

  2006cited by this paper
• Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

  2006cited by this paper
• Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.

  2006cited by this paper
• Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

  2005cited by this paper
• The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

  2001cited by this paper
• Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha.

  1998cited by this paper
• Epidermal growth factor.

  1990cited by this paper

• EGFR mutations in non-small cell lung cancer: Classification, characteristics and resistance to third-generation EGFR-tyrosine kinase inhibitors (Review)

  2025cites this paper
• Integrated Computational Approach for Designing Potent EGFR‐TK Inhibitors: QSAR, Docking, ADMET, and Molecular Dynamics Studies

  2025cites this paper
• Tuning isatoic anhydrides’ lysine ligation chemistry for bioconjugation and drug delivery

  2024cites this paper
• Computational Analysis of Drug Resistance Network in Lung Adenocarcinoma.

  2021cites this paper
• A Review: Discovering 1,3,4-oxadiazole and chalcone nucleus for cytotoxicity/EGFR inhibitory anticancer activity.

  2021cites this paper
• The proteome-wide potential for reversible covalency at cysteine.

  2019cites this paper
• 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.

  2019cites this paper
• New Iminodiacetate-Thiosemicarbazone Hybrids and Their Copper(II) Complexes Are Potential Ribonucleotide Reductase R2 Inhibitors with High Antiproliferative Activity.

  2017cites this paper
• COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo

  2016cites this paper
• The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines.

  2016cites this paper